アンチコンプリメントペプチドアナログのための準ダイナミックなファルマコフォアモデルの開発
Buddhadeb Mallik1, Dimitrios Morikis
1Department of Chemical and Environmental Engineering, University of California at Riverside, Riverside, CA 92521, USA.
Journal of the American Chemical Society
|August 4, 2005
まとめ
コンプスタチンという補足抑制ペプチドの薬理学モデルが,分子ダイナミクスを用いて開発された. 2次元のモデルは,有効な同類体と非有効な同類体を効果的に区別し,薬物設計におけるペプチドの柔軟性を強調しました.
科学分野:
- 計算化学と分子モデリング
- 薬剤の発見と医薬品化学
- 構造生物学とペプチド科学
背景:
- コンプスタチンは,コンプリメントシステムのペプチド阻害剤であり,先天性免疫の重要な部分です.
- コンプスタチンの構造と作用の関係を理解することは,新しい治療法の開発に不可欠です.
- ファルマコフォアモデリングは,薬剤設計における重要な技術ですが,柔軟なペプチドへの応用は課題を提示します.
研究 の 目的:
- コンプレメント阻害ペプチドコンプスタチンの準ダイナミックなファルマコフォアモデルを構築する.
- 活性および非活性コンプスタチンアナログを区別する異なる薬理学モデルの能力を評価する.
- ファーマコフォアモデル開発と活性予測に対するペプチドの柔軟性の影響を調査する.
主な方法:
- 5ns分子ダイナミクスシミュレーションを用いてコンプスタチンおよび同類薬のダイナミックコンフォマーを生成.
- 物理化学的および構造的性質を組み込んだ3つの準動的薬理型モデルを構築しました.
- ファルマコフォアの特徴 (距離,角度,二面角) の1次元および2次元確率分布を分析した.
主要な成果:
- 一次元のモデルでは,コンプスタチンの類似品の広範囲で重複する分布を示した.
- 二次元の距離角度モデルでは,類似を部分的に区別したが,アクティブと非アクティブのグループを分離することはできなかった.
- 二次元の距離二面角モデルでは,アクティブと非アクティブのコンプスタチンの類型を効果的に区別し,最も高い活性のアナログの特徴的な振る舞いを示しました.
結論:
- 頑固な有機分子と比較して柔軟なペプチドの薬理学モデル化には,より厳格な構造的制約が必要である.
- ペプチドの柔軟性は,リガンドベースの薬剤ホルダー設計において明示的に考慮されなければならない.
- アクティビティの差別化のための多次元確率表面の有効性は,システムに依存し,トレーニングセット,シミュレーションプロトコル,およびファルマコフォールポイントの選択の影響を受けます.
さらに関連する動画
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
06:51Microfluidic Model of Necrotizing Enterocolitis Incorporating Human Neonatal Intestinal Enteroids and a Dysbiotic Microbiome
Published on: July 28, 2023
関連する概念動画
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).